The Efficacy and Safety of Black Rice Bran Extract on Immune Enhancement
NCT04940910 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2021-06-28
Summary
This study was conducted to investigate the efficacy and safety of Black rice bran extract on immune enhancement.
Conditions
- Immunity
Interventions
- DIETARY_SUPPLEMENT
-
Black rice bran extract
2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
- DIETARY_SUPPLEMENT
-
Placebo
2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
Sponsors & Collaborators
-
Chonbuk National University Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-02-22
- Primary Completion
- 2021-05-07
- Completion
- 2021-06-25
Countries
- South Korea
Study Locations
More Related Trials
-
Infections Associated With the Use of Alemtuzumab
NCT01315457 ·Status: COMPLETED
-
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
NCT04324996 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
NCT00823524 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Thymosin Alpha-1 for irAE Secondary to ICIs
NCT06178146 ·Status: RECRUITING ·Phase: PHASE4
-
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
NCT01795378 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency
NCT00011141 ·Status: COMPLETED ·Phase: NA
-
Immune Cell Response to Stimuli
NCT00397280 ·Status: RECRUITING
-
Fase I Clinical Trial on NK Cells for COVID-19
NCT04634370 ·Status: UNKNOWN ·Phase: PHASE1
-
Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals
NCT01784692 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)
NCT02425748 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases
NCT06877364 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade
NCT04616235 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of γδ T Cell Against Gastric Cancer
NCT02585908 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients
NCT02565589 ·Status: COMPLETED
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
NCT04264858 ·Status: UNKNOWN ·Phase: NA
-
Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19
NCT04797975 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT02496273 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Immune Modulation by Exosomes in COVID-19
NCT05191381 ·Status: RECRUITING
-
Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
NCT06040918 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.
NCT02602249 ·Status: UNKNOWN ·Phase: PHASE1
-
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
NCT03882840 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Functional Characterization of CD8+ T Cells After Supramaximal Exercise
NCT06484101 ·Status: COMPLETED ·Phase: NA
-
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
NCT04298502 ·Status: UNKNOWN
-
Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
NCT01801852 ·Status: UNKNOWN ·Phase: NA